Wall Street analyst estimates for Dare Bioscience, Inc. (DARE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.14 | ||
| 2026-08-13 | $-0.20 | $-0.30 | +32.6% |
| 2026-05-14 | $-0.20 | $-0.33 | +39.4% |
| 2026-03-26 | $-0.02 | $-0.24 | +91.7% |
| 2025-11-13 | $-0.28 | $-0.33 | +15.2% |
| 2025-08-14 | $-0.45 | $-0.55 | +18.2% |
| 2025-05-13 | $-0.50 | $-0.63 | +20.6% |
| 2025-03-31 | $-0.64 | $-0.66 | +3.0% |
Valuation Ratios
| Price / Book | -18.96 |
| EV / EBITDA | -0.53 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $766000 | 0 | 0 | 0 | 0 | 0 | $10.0M | $2.8M | $9784 | $1.0M |
| Cost of Revenue | $400000 | 0 | $625000 | $11137 | $83333 | $100000 | $30.1M | $21.6M | $14.3M | $2.4M |
| Gross Profit | $366000 | 0 | -$2440 | -$11137 | -$83333 | -$100000 | -$20.1M | -$18.8M | -$14.3M | -$1.4M |
| Research & Development | $27.6M | $984749 | $6.4M | $8.5M | $20.8M | $30.6M | $30.0M | $21.5M | $14.2M | $5.52B |
| Selling, General & Admin | $10.4M | $2.7M | $5.3M | $5.8M | $6.5M | $8.4M | $11.2M | $11.9M | $9.2M | $8.8M |
| Operating Expenses | $37.9M | $3.7M | $11.7M | $14.3M | $27.3M | $39.0M | $11.2M | $12.1M | $9.2M | $12.1M |
| Operating Income | -$37.2M | -$11.2M | -$16.9M | -$14.3M | -$27.4M | -$39.1M | -$31.4M | -$30.9M | -$23.5M | -$13.6M |
| EBITDA | -$36.8M | -$11.2M | -$11.7M | -$14.3M | -$27.4M | -$38.7M | -$30.9M | -$30.7M | -$4.0M | -$10.4M |
| Interest Expense | $2.2M | $322629 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $822709 |
| Pre-tax Income | -$39.3M | -$11.5M | -$16.7M | -$14.3M | -$27.4M | -$38.7M | -$30.9M | -$30.2M | -$4.1M | -$13.4M |
| Income Tax | $86000 | 0 | $10.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$39.3M | -$11.5M | -$16.7M | -$14.3M | -$27.4M | -$38.7M | -$30.9M | -$30.2M | -$4.1M | -$13.4M |
| EPS | $-30.02 | $-3.56 | $-30.16 | $-10.99 | $-10.93 | $-7.52 | $-4.39 | $-4.15 | $-0.48 | $-1.20 |
| EPS (Diluted) | $-30.02 | $-3.56 | $-30.16 | $-10.99 | $-10.93 | $-7.52 | $-4.39 | $-4.15 | $-0.48 | $-1.20 |
| Shares Outstanding (Diluted) | $1.3M | $269356 | $894368 | $1.3M | $2.5M | $5.1M | $7.0M | $7.3M | $8.5M | $111.8M |
Price
| Price | $0.73 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADTX · AIMD · ANL · ASBP · ATHA · CTXR · FBLG
Explore sector: Healthcare · Biotechnology
More sections of DARE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks